Non replicating viral vector for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
Asano NCT04568031		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	placebo	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive
AstraZeneca phase 3 US (D8110C00001) NCT04516746		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	placebo	COVID-19 prophylaxis (excluding children)	NA	21583/10796	safety concern	suggested 76 % decrease in symptomatic Covid-19 statistically significant 62 % increase in adverse events statistically significant vaccine efficacy of 78.9% in preventing symptomatic COVID-19 and 100% efficacy in preventing severe or critical disease and hospitalization. In participants 65 years and older, who comprised 20% of the trial population, vaccine efficacy against symptomatic COVID-19 was 79.9%
Fengcai NCT04566770		RCT	CanSino (Convidecia)	placebo	COVID-19 prophylaxis (excluding children)	NA	320/110	safety concern	statistically significant 19.2-fold increase in systemic adverse reaction, any, dose 1 statistically significant 3.4-fold increase in systemic adverse reaction, any, dose 2
Kulkarni CTRI/2020/08/027170		RCT	Covishield (Oxford/AZ formulation)	placebo	COVID-19 prophylaxis (excluding children)	NA	1200/300	inconclusive	There were no thromboembolic-associated or autoimmune-related SAEs
Sadoff NCT04436276		RCT	Janssen AD26 vaccine (JNJ-78436735)	placebo	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive	Interim Results of a Phase 1–2a Trial : cohort 1 (healthy adults 18-55y) and 3 (>65y). Data that are reported here were collected after the administration of the second dose (either vaccine or placebo) in cohort 1a and after the first dose in cohort 3
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	12282/11962	inconclusive	pooled data of four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), andNCT04444674 (COV005)
CanSino phase 2 (Zhu) NCT04341389		RCT	CanSino (Convidecia)	placebo	COVID-19 prophylaxis (excluding children)	NA	382/126	inconclusive	No serious adverse events were documented within 28 days
ChAdOx1 phase 3 (AstraZeneca) NCT04400838		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	some concern	5807/5829	conclusif	demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
RESIST (Sputnik V Gamaleya Research Institute Russia) NCT04530396		RCT	Sputnik V (Gam-COVID-Vac)	placebo	COVID-19 prophylaxis (excluding children)	high	16501/5476	suggested	suggested 73 % decrease in confirmed Covid-19, from 1st dose but with a low degree of certainty due to high risk of bias suggested 92 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias
ENSEMBLE (COV3001) unpublished NCT04505722		RCT	Janssen AD26 vaccine (JNJ-78436735)	placebo	COVID-19 prophylaxis (excluding children)	some concern	21895/21888	conclusif	suggested 81 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 82 % decrease in hospitalization with a moderate degree of certainty due to some concern in risk of bias
Scotland cohort unpublished		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested
EPIPHARE (Janssen)		OBS	Janssen AD26 vaccine (JNJ-78436735)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 75 % increase in Myocardial infarction
EPIPHARE (Vaxzevria)		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 29 % increase in Myocardial infarction statistically significant 41 % increase in pulmonary embolism
Hippisley-Cox		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 10 % increase in venous thromboembolism
Husby (janssen)		OBS	Janssen AD26 vaccine (JNJ-78436735)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	inconclusive
Patone		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 1.3-fold increase in Guillain-Barré syndrome statistically significant 1.0-fold increase in Guillain-Barré syndrome
Simpson (ChAdOx1)		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	safety concern	statistically significant 98 % increase in immune thrombocytopenia
Nabirova		OBS	Sputnik V (Gam-COVID-Vac)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 77 % decrease in new illness compatible with Covid-19
Bernal (PHE, 19th February 2021)		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	no results
Burn (Vaxzevria)		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	critical	-/-	safety concern	statistically significant 1.0-fold increase in immune thrombocytopenia but with a very low degree of certainty due to critical risk of bias statistically significant 23 % increase in pulmonary embolism but with a very low degree of certainty due to critical risk of bias statistically significant 25 % increase in thrombocytopenia but with a very low degree of certainty due to critical risk of bias
Edward (Vaxzevria)		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	critical	-/-	inconclusive
Bernal unpublished		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	NA	-/-	suggested	suggested 55 % decrease in deaths,deaths
Pottegard		OBS	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	critical	-/-	safety concern	statistically significant 1.3-fold increase in intracranial hemorrhage but with a very low degree of certainty due to critical risk of bias statistically significant 79 % increase in pulmonary embolism but with a very low degree of certainty due to critical risk of bias statistically significant 2.0-fold increase in thrombocytopenia but with a very low degree of certainty due to critical risk of bias statistically significant 97 % increase in venous thromboembolism but with a very low degree of certainty due to critical risk of bias statistically significant 19.3-fold increase in cerebral venous sinus thrombosis (CVST) but with a very low degree of certainty due to critical risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis